News | November 10, 2023
Aurobindo Pharma posts Q2 FY 24 up 84% at Rs. 752 Cr
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
Aurobindo Pharma has reported total income of Rs. 6966.85 crores during the period ended June 30, 2023
The product is being launched in August 2023
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Aurobindo will respond to the US FDA within the stipulated timelines
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
The product is expected to be launched in June 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
